Ivabradine is indicated in heart failure patients under which combination?

Ivabradine is indicated in heart failure patients under which combination?

• A. EF <50% with HR ≥70 bpm
• B. EF <35% and resting HR ≥70 bpm in AF
• C. EF <40% with HR ≥90 bpm
• D. EF <35% and resting HR ≥70 bpm in sinus rhythm

Answer: (D)

Ivabradine works by selectively blocking the If current in the sinoatrial node to slow the heart rate. In chronic systolic heart failure, reducing heart rate can lower myocardial oxygen demand and improve diastolic filling, which helps reduce HF hospitalizations when symptoms persist despite standard therapy. The best-supported indication is in patients with left ventricular ejection fraction ≤35% who have a resting heart rate of ≥70 beats per minute and are in sinus rhythm. The sinus rhythm requirement matters because ivabradine acts on the SA node and requires normal atrioventricular conduction to slow the rate effectively; in atrial fibrillation the mechanism doesn’t apply the same way and benefits aren’t established. The ≥70 bpm threshold comes from trial data showing benefit in patients with higher resting rates, while the EF criterion identifies those with systolic dysfunction who stand to gain from rate reduction. Other scenarios—such as AF, higher or lower EF cutoffs, or different HR thresholds—don’t meet the approved indication.

Ivabradine works by selectively blocking the If current in the sinoatrial node to slow the heart rate. In chronic systolic heart failure, reducing heart rate can lower myocardial oxygen demand and improve diastolic filling, which helps reduce HF hospitalizations when symptoms persist despite standard therapy.

The best-supported indication is in patients with left ventricular ejection fraction ≤35% who have a resting heart rate of ≥70 beats per minute and are in sinus rhythm. The sinus rhythm requirement matters because ivabradine acts on the SA node and requires normal atrioventricular conduction to slow the rate effectively; in atrial fibrillation the mechanism doesn’t apply the same way and benefits aren’t established. The ≥70 bpm threshold comes from trial data showing benefit in patients with higher resting rates, while the EF criterion identifies those with systolic dysfunction who stand to gain from rate reduction. Other scenarios—such as AF, higher or lower EF cutoffs, or different HR thresholds—don’t meet the approved indication.